Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Bioengineered self-assembled nanofibrils for high-affinity SARS-CoV-2 capture and neutralization

  • Behbahanipour, Molood|||0000-0002-7889-6105
  • Navarro, Susanna|||0000-0001-8160-9536
  • Bárcenas, Oriol|||0000-0002-8439-4005
  • Garcia-Pardo, Javier|||0000-0001-9179-6371
  • Ventura, Salvador|||0000-0002-9652-6351
The recent coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spurred intense research efforts to develop new materials with antiviral activity. In this study, we genetically engineered amyloid-based nanofibrils for capturing and neutralizing SARS-CoV-2. Building upon the amyloid properties of a short Sup35 yeast prion sequence, we fused it to SARS-CoV-2 receptor-binding domain (RBD) capturing proteins, LCB1 and LCB3. By tuning the reaction conditions, we achieved the spontaneous self-assembly of the Sup35-LCB1 fusion protein into a highly homogeneous and well-dispersed amyloid-like fibrillar material. These nanofibrils exhibited high affinity for the SARS-CoV-2 RBD, effectively inhibiting its interaction with the angiotensin-converting enzyme 2 (ACE2) receptor, the primary entry point for the virus into host cells. We further demonstrate that this functional nanomaterial entraps and neutralizes SARS-CoV-2 virus-like particles (VLPs), with a potency comparable to that of therapeutic antibodies. As a proof of concept, we successfully fabricated patterned surfaces that selectively capture SARS-CoV-2 RBD protein on wet environments. Collectively, these findings suggest that these protein-only nanofibrils hold promise as disinfecting coatings endowed with selective SARS-CoV-2 neutralizing properties to combat viral spread or in the development of sensitive viral sampling and diagnostic tools.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Aggrescan4D, structure-informed analysis of pH-dependent protein aggregation

  • Bárcenas, Oriol|||0000-0002-8439-4005
  • Kuriata, Aleksander
  • Zalewski, Mateusz|||0000-0002-3436-8829
  • Iglesias, Valentin|||0000-0002-6133-0869
  • Pintado-Grima, Carlos|||0000-0002-8544-959X
  • Firlik, Grzegorz
  • Burdukiewicz, Michał|||0000-0001-8926-582X
  • Kmiecik, Sebastian|||0000-0001-7623-0935
  • Ventura, Salvador|||0000-0002-9652-6351
Protein aggregation is behind the genesis of incurable diseases and imposes constraints on drug discovery and the industrial production and formulation of proteins. Over the years, we have been advancing the Aggresscan3D (A3D) method, aiming to deepen our comprehension of protein aggregation and assist the engineering of protein solubility. Since its inception, A3D has become one of the most popular structure-based aggregation predictors because of its performance, modular functionalities, RESTful service for extensive screenings, and intuitive user interface. Building on this foundation, we introduce Aggrescan4D (A4D), significantly extending A3D's functionality. A4D is aimed at predicting the pH-dependent aggregation of protein structures, and features an evolutionary-informed automatic mutation protocol to engineer protein solubility without compromising structure and stability. It also integrates precalculated results for the nearly 500,000 jobs in the A3D Model Organisms Database and structure retrieval from the AlphaFold database. Globally, A4D constitutes a comprehensive tool for understanding, predicting, and designing solutions for specific protein aggregation challenges. The A4D web server and extensive documentation are available at . This website is free and open to all users without a login requirement.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Structural information in therapeutic peptides, Emerging applications in biomedicine

  • Iglesias, Valentin|||0000-0002-6133-0869
  • Bárcenas, Oriol|||0000-0002-8439-4005
  • Pintado-Grima, Carlos|||0000-0002-8544-959X
  • Burdukiewicz, Michał|||0000-0001-8926-582X
  • Ventura, Salvador|||0000-0002-9652-6351
Peptides are attracting a growing interest as therapeutic agents. This trend stems from their cost-effectiveness and reduced immunogenicity, compared to antibodies or recombinant proteins, but also from their ability to dock and interfere with large protein-protein interaction surfaces, and their higher specificity and better biocompatibility relative to organic molecules. Many tools have been developed to understand, predict, and engineer peptide function. However, most state-of-the-art approaches treat peptides only as linear entities and disregard their structural arrangement. Yet, structural details are critical for peptide properties such as solubility, stability, or binding affinities. Recent advances in peptide structure prediction have successfully addressed the scarcity of confidently determined peptide structures. This review will explore different therapeutic and biotechnological applications of peptides and their assemblies, emphasizing the importance of integrating structural information to advance these endeavors effectively.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Multivalent Protein Nanorings for Broad and Potent SARS-CoV-2 Neutralization

  • Behbahanipour, Molood|||0000-0002-7889-6105
  • Goldin, Carla|||0000-0001-8996-4153
  • Prato, Cecilia Arahi
  • Paletta, Ana Luz|||0000-0003-2181-8488
  • Bárcenas, Oriol|||0000-0002-8439-4005
  • Navarro, Susanna|||0000-0001-8160-9536
  • Pujols Pujol, Jordi|||0000-0001-9424-5866
  • Murgida, Daniel H.
  • Tribulatti, María Virginia|||0000-0003-0507-065X
  • Esperante, Sebastián|||0000-0002-5778-6871
  • Alvarez-Paggi, Damian|||0000-0002-1507-9685
  • Ventura, Salvador|||0000-0002-9652-6351
The ongoing threat of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the limitations of conventional antibody-based therapeutics (ABTs) underscore the need for scalable and customizable antiviral platforms. A modular, protein-only nanoscaffold based on recombinant ring-like particles (RLPs) derived from a viral nucleoprotein (NP), engineered is presented to display high-affinity, de novo-designed minibinders (LCB1 and LCB3) targeting SARS-CoV-2 Spike (S)protein. These binders are site-specifically fused to either the N- or C-termini, or both ends of NP to ensure functional orientation and dense, multivalent display. The resulting constructs self-assemble into stable, biocompatible, and homogeneous nanoparticles that potently inhibit S-angiotensin-converting enzyme 2 receptor (ACE2r) interactions, neutralizing both pseudotyped viral-like particles and authentic SARS-CoV-2, including Omicron BA.5. The dual-display nanoparticle (RLP-1,3), presenting 10 LCB1 and 10 LCB3 domains, exhibit synergistic binding activity, with fM Half Maximal Inhibitory Concentration(IC) values, outperforming benchmark monoclonal antibodies and clinically approved hyperimmune therapies. Additionally, RLP-1,3 is adapted for diagnostics in an ELISA platform, achieving a Spike protein detection limit of 9 ng mL, surpassing commercial assays. This work demonstrates how the convergence of AI-guided binder design and structure-based nanoscaffolding enables next-generation multifunctional bio-nanomaterials. The RLP-minibinder system offers a generalizable, scalable, and cost-efficient plug-and-(dis)play solution with integrated therapeutic and diagnostic capabilities, positioning it as a flexible alternative to ABTs for pandemic preparedness.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

AGGRESCAN and its evolution, A two-decade perspective on protein aggregation prediction

  • Pesce, Giulia|||0000-0002-3979-6072
  • Solé Pozas, Josep Oriol|||0009-0008-0005-6174
  • Bárcenas, Oriol|||0000-0002-8439-4005
  • Ventura, Salvador|||0000-0002-9652-6351
Protein aggregation is a widespread phenomenon with profound biological, biomedical, and biotechnological implications. In human disease, aberrant protein self-assembly is a hallmark of numerous neurodegenerative disorders, whereas in the biopharmaceutical industry, aggregation complicates the production, stability, and formulation of therapeutic proteins. The Aggrescan platform was one of the first empirically based tools designed to predict aggregation-prone regions (APRs) within protein sequences. It has since expanded to incorporate three-dimensional structural contexts and environmental conditions. This review provides a comprehensive overview of the development, application, and impact of the Aggrescan family of tools, which includes AGGRESCAN, Aggrescan3D, and the recent Aggrescan4D. We examine the algorithmic foundations, empirical validation, and key use cases spanning fields from biotechnology to biomedical research. Additionally, we describe how the recent integration of AlphaFold models has enabled proteome-scale exploration of aggregation determinants. This review highlights how Aggrescan has evolved alongside with advances in the field, becoming a reliable and accessible tool for studying and redesigning protein aggregation.